Inflammation, obesity, and metabolic syndrome in depression: Analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES)

Journal of Clinical Psychiatry

Volumn 75, Issue 12, 2014, Pages e1428-e1432

  Rethorst, Chad D ^a   Bernstein, Ira ^a   Trivedi, Madhukar H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DEPRESSION; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PATIENT HEALTH QUESTIONNAIRE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SELF REPORT; WAIST CIRCUMFERENCE; ADOLESCENT; ADULT; BLOOD; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; METABOLISM; MIDDLE AGED; NUTRITION; RISK FACTOR; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; C-REACTIVE PROTEIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NUTRITION SURVEYS; OBESITY; PREVALENCE; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84932100510     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/jcp.14m09009     Document Type: Article

References (37)

1. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64(12):1465-1475. doi:10.4088/JCP.v64n1211 PubMed
2. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747-1757. doi:10.1016/S0140-6736(06)68770-9 PubMed
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psychiatry. 2006;163(11):1905-1917. doi:10.1176/appi.ajp.163.11.1905 PubMed
4. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR∗D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. doi:10.1176/appi.ajp.163.1.28 PubMed
5. Andrews G, Sanderson K, Corry J, et al. Using epidemiological data to model efficiency in reducing the burden of depression. J Ment Health Policy Econ. 2000;3(4):175-186. doi:10.1002/mhp.96 PubMed
6. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457. doi:10.1016/j.biopsych.2009.09.033 PubMed
7. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2): 171-186. doi:10.1097/PSY.0b013e3181907c1b PubMed
8. Prather AA, Carroll JE, Fury JM, et al. Gender differences in stimulated cytokine production following acute psychological stress. Brain Behav Immun. 2009;23(5):622-628. doi:10.1016/j.bbi.2008.11.004 PubMed
9. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology. 2011;36(12):2452-2459. doi:10.1038/npp.2011.132 PubMed
10. Lanquillon S, Krieg JC, Bening-Abu-Shach U, et al. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000;22(4):370-379. doi:10.1016/S0893-133X(99)00134-7 PubMed
11. Benedetti F, Lucca A, Brambilla F, et al. Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(6):1167-1170. doi:10.1016/S0278-5846(02)00255-5 PubMed
12. Mikova O, Yakimova R, Bosmans E, et al. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol. 2001;11(3):203-208. doi:10.1016/S0924-977X(01)00081-5 PubMed
13. Eller T, Vasar V, Shlik J, et al. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):445-450. doi:10.1016/j.pnpbp.2007.09.015 PubMed
14. Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology. 1997;35(3):123-127. doi:10.1159/000119332 PubMed
15. Koponen H, Jokelainen J, Keinänen-Kiukaanniemi S, et al. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J Clin Psychiatry. 2008;69(2):178-182. doi:10.4088/JCP.v69n0202 PubMed
16. Goldbacher EM, Bromberger J, Matthews KA. Lifetime history of major depression predicts the development of the metabolic syndrome in middleaged women. Psychosom Med. 2009;71(3):266-272. doi:10.1097/PSY.0b013e318197a4d5 PubMed
17. Kinder LS, Carnethon MR, Palaniappan LP, et al. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med. 2004;66(3):316-322. doi:10.1097/01.psy.0000124755.91880.f4 PubMed
18. Capuron L, Su S, Miller AH, et al. Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry. 2008;64(10):896-900. doi:10.1016/j.biopsych.2008.05.019 PubMed
19. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. doi:10.1046/j.1525-1497.2001.016009606.x PubMed
20. Grundy SM, Cleeman JI, Daniels SR, et al National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-2752. doi:10.1161/CIRCULATIONAHA.105.169404 PubMed
21. Pearson TA, Mensah GA, Alexander RW, et al American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511. doi:10.1161/01.CIR.0000052939.59093.45 PubMed
22. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among US adults: NHANES III to NHANES 1999-2006. Diabetes Care. 2011;34(1):216-219. doi:10.2337/dc10-0879 PubMed
23. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851-858. doi:10.1016/S0140-6736(07)61415-9 PubMed
24. Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. J Affect Disord. 2002;72(3):227-236. doi:10.1016/S0165-0327(01)00413-X PubMed
25. Toups MS, Trivedi MH. The role of metabolic dysfunction in treatment resistance of major depressive disorder. Neuropsychiatry. 2011;1(5):441-455. doi:10.2217/npy.11.49
26. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41. doi:10.1001/2013.jamapsychiatry.4 PubMed
27. Mehta D, Raison CL, Woolwine BJ, et al. Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain Behav Immun. 2013;31:205-215. doi:10.1016/j.bbi.2013.04.004 PubMed
28. Rethorst CD, Toups MS, Greer TL, et al. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry. 2013;18(10):1119-1124. doi:10.1038/mp.2012.125 PubMed
29. Toups MS, Greer TL, Kurian BT, et al. Effects of serum Brain Derived Neurotrophic Factor on exercise augmentation treatment of depression. J Psychiatr Res. 2011;45(10):1301-1306. doi:10.1016/j.jpsychires.2011.05.002 PubMed
30. Lamers F, de Jonge P, Nolen WA, et al. Identifying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2010;71(12):1582-1589. doi:10.4088/JCP.09m05398blu PubMed
31. Lamers F, Vogelzangs N, Merikangas KR, et al. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry. 2013;18(6):692-699. doi:10.1038/mp.2012.144 PubMed
32. Chou KL, Yu KM. Atypical depressive symptoms and obesity in a national sample of older adults with major depressive disorder. Depress Anxiety. 2013;30(6):574-579. doi:10.1002/da.22098 PubMed
33. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(suppl 11):37-41. PubMed
34. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(suppl 4):8-13. PubMed
35. Ford ES. Does exercise reduce inflammation? physical activity and C-reactive protein among US adults. Epidemiology. 2002;13(5):561-568. doi:10.1097/00001648-200209000-00012 PubMed
36. Ford ES, Kohl HW 3rd, Mokdad AH, et al. Sedentary behavior, physical activity, and the metabolic syndrome among US adults. Obes Res. 2005;13(3):608-614. doi:10.1038/oby.2005.65 PubMed
37. Rethorst CD, Moynihan J, Lyness JM, et al. Moderating effects of moderateintensity physical activity in the relationship between depressive symptoms and interleukin-6 in primary care patients. Psychosom Med. 2011;73(3):265-269. doi:10.1097/PSY.0b013e3182108412 PubMed